TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28733943

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections (70 to 150 U per session, targeted to pericranial myofascial sites)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA injections
Number of subjects: 63
Study: 28734628

Group type: EXPERIMENTAL
Intervention: ADRA2A_2790CC genotype
Number of subjects: 351

Group type: COMPARATOR
Intervention: CT/TT genotypes
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Post-Norwood complications
Number of subjects: 351
Study: 28734829

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy during vaginal hysterectomy
Number of subjects: 74
Study: 28735291

Group type: EXPERIMENTAL
Intervention: Combination of low coronary artery calcium score and low high-sensitivity cardiac troponin T
Number of subjects: 532

Group type: EXPERIMENTAL
Intervention: Lower high-sensitivity cardiac troponin T and coronary artery calcium
Number of subjects: 532
Study: 28735759

Group type: EXPERIMENTAL
Intervention: Tooth loss levels (measured as number of teeth: 26-32, 20-25, 15-19, 1-14, No Teeth)
Number of subjects: 15456
Study: 28736110

Group type: EXPERIMENTAL
Intervention: Pulsatile autoregulated artificial heart
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28736443

Group type: EXPERIMENTAL
Intervention: CLOCK 3111C carriers (CC and TC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: TT carriers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Weight loss during treatment program
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Rhythmicity-weight loss associations
Number of subjects: 40
Study: 28736545

Group type: EXPERIMENTAL
Intervention: Mirror therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 28736819

Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (clinically healthy individuals)
Number of subjects: 20
Study: 28738781

Group type: EXPERIMENTAL
Intervention: Cardiac Magnetic Resonance (CMR) imaging technique
Number of subjects: 150

Group type: COMPARATOR
Intervention: CMR imaging
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Coronary arteries evaluated by computed tomography angiography
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Questionnaires for Quality-of-Life (QoL)
Number of subjects: 150
Study: 28738791

Group type: EXPERIMENTAL
Intervention: Anthropometric indices (BMI, height, weight)
Number of subjects: 7268

Group type: EXPERIMENTAL
Intervention: Percent stunted (<-2SD height for age z-score)
Number of subjects: 7268

Group type: EXPERIMENTAL
Intervention: % underweight (BMI <18.5)
Number of subjects: 7268

Group type: EXPERIMENTAL
Intervention: % overweight/obese (BMI ≥25.0)
Number of subjects: 7268

Group type: EXPERIMENTAL
Intervention: Socioeconomic status (SES) and age correlation with BMI
Number of subjects: 7268

Group type: EXPERIMENTAL
Intervention: Age correlation with weight status
Number of subjects: 7268
Study: 28738797

Group type: EXPERIMENTAL
Intervention: TTC arthrodesis with reverse PHILOS plate and medial cannulated screw
Number of subjects: 12
Study: 28738902

Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Support Empowerment Model
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Chronic Care Model
Number of subjects: 240
Study: 28739783

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg, once daily)
Number of subjects: 15
Study: 28740058

Group type: EXPERIMENTAL
Intervention: No-cutpoint networks
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Only-family networks
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Network size
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 1384
Study: 28740367

Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle changes and/or metformin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28740411

Group type: EXPERIMENTAL
Intervention: Telehealthcare intervention for patients with COPD
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Telehealthcare intervention for patients younger than 60 years
Number of subjects: 1225

Group type: EXPERIMENTAL
Intervention: Subgroup analyses across various factors (comorbidities, age-groups, genders, resource patterns, delivery sites)
Number of subjects: 1225
Study: 28740869

Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) and RNA sequencing (RNA-seq)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IBM Watson Genomic Analytics (WGA)
Number of subjects: 0
Study: 28741071

Group type: EXPERIMENTAL
Intervention: lanreotide depot/autogel (LAN)
Number of subjects: 241
Study: 28742292

Group type: EXPERIMENTAL
Intervention: Right unilateral ultrabrief pulse ECT combined with venlafaxine
Number of subjects: 240
Study: 28742709

Group type: EXPERIMENTAL
Intervention: Near-infrared cholangiography (NIR-C)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Three-dimensional virtual reality (VR)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: X-ray intraoperative cholangiography (IOC)
Number of subjects: 58
Study: 28743102

Group type: EXPERIMENTAL
Intervention: Delirium screening using the Intensive Care Delirium Screening Checklist or the Confusion Assessment Method for the Intensive Care Unit
Number of subjects: 0
Study: 28743198

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Relaxation Therapy (RT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Overall Results
Number of subjects: 50
Study: 28743681

Group type: EXPERIMENTAL
Intervention: Intelligent Pain Management System (IPMS)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional methods (control group)
Number of subjects: 46
Study: 28743683

Group type: EXPERIMENTAL
Intervention: Smokers of conventional cigarettes
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Ex-smokers (quit smoking 1 to 5 years ago)
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Never-smokers
Number of subjects: 900
Study: 28744217

Group type: EXPERIMENTAL
Intervention: Busulfan-cyclophosphamide (BU-CY) conditioning regimen
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Univariate analysis of HC incidence
Number of subjects: 72
Study: 28744244

Group type: EXPERIMENTAL
Intervention: Behavioral Teacher Program targeting ADHD symptoms
Number of subjects: 0
Study: 28744716

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening via fecal testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening via colonoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colorectal cancer screening overall
Number of subjects: 0
Study: 28745646

Group type: EXPERIMENTAL
Intervention: Sternberg Working Memory paradigm during threat of shock
Number of subjects: 0

Group type: COMPARATOR
Intervention: Threat of shock condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safe condition
Number of subjects: 0
Study: 28746812

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous adipose tissue-derived mesenchymal stem cells (AD MSCs)
Number of subjects: 18
Study: 28747021

Group type: EXPERIMENTAL
Intervention: Medically managed NSTE-ACS patients
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: CAG- group
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: CAG+ CAD- group
Number of subjects: 2272

Group type: EXPERIMENTAL
Intervention: CAG+ CAD+ group
Number of subjects: 2272
Study: 28747274

Group type: EXPERIMENTAL
Intervention: On-demand PrEP (tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg) taken before and after sexual intercourse
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: On-demand PrEP
Number of subjects: 361
Study: 28747397

Group type: EXPERIMENTAL
Intervention: Patients with STEMI
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 11
Study: 28747452

Group type: EXPERIMENTAL
Intervention: MRI-guided focused ultrasound thalamotomy (MRgFUS) targeting the ventro-intermedius nucleus (Vim) of the dominant hemisphere
Number of subjects: 6
Study: 28747857

Group type: EXPERIMENTAL
Intervention: Culturally adapted cessation intervention (treatment arm) with nicotine patches for 8 weeks
Number of subjects: 97

Group type: COMPARATOR
Intervention: Standard cognitive behavioral therapy (comparison arm) with nicotine patches for 8 weeks
Number of subjects: 97
Study: 28748214

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing
Number of subjects: 1
Study: 28750271

Group type: EXPERIMENTAL
Intervention: LY2780301 500 mg QD plus gemcitabine 750 mg/m²
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LY2780301 400 mg QD plus gemcitabine 1000 mg/m²
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LY2780301 500 mg QD plus gemcitabine 1000 mg/m²
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: LY2780301 400 mg QD plus gemcitabine 750 mg/m²
Number of subjects: 50
Study: 28750429

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with diabetes
Number of subjects: 2430
Study: 28750603

Group type: EXPERIMENTAL
Intervention: Fitts' Reciprocal Aiming Task v.1.0 (Horizontal) with smaller targets
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Fitts' Reciprocal Aiming Task v.1.0 (Horizontal) with speed demands
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comparison of CP group to typical development (TD) group
Number of subjects: 48
Study: 28750608

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 469

Group type: COMPARATOR
Intervention: Anti-arrhythmic drug therapy
Number of subjects: 469
Study: 28750642

Group type: EXPERIMENTAL
Intervention: CMR fluoroscopy guided right heart catheterization (RHC)
Number of subjects: 102
Study: 28750659

Group type: EXPERIMENTAL
Intervention: 8 cycles of modified FOLFIRINOX (oxaliplatin 85 mg/m2, details of other drugs not provided)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Chemotherapy plus hypofractionated radiation therapy
Number of subjects: 134
Study: 28750671

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid analysis
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blood analysis
Number of subjects: 24
Study: 28750697

Group type: EXPERIMENTAL
Intervention: Temperature-controlled irrigated RF catheter (DiamondTemp)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard force-sensing catheter (control)
Number of subjects: 70
Study: 28751001

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 or 10 mg BID
Number of subjects: 0
Study: 28751088

Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia group (Hypo-AG, serum albumin <28 g/L)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Marginal hypoalbuminemia group (Margin-AG, serum albumin 28-34.9 g/L)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: Normal albuminemia group (Normal-AG, serum albumin ≥35 g/L)
Number of subjects: 426
Study: 28751125

Group type: EXPERIMENTAL
Intervention: Youth with Down syndrome (DS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Youth without Down syndrome (non-DS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth without DS with obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Youth with DS with obesity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregivers of youth with DS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caregivers of youth with obesity (regardless of DS status)
Number of subjects: 0
Study: 28751247

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 or 160 mg daily)
Number of subjects: 61
Study: 28751558

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 1505
Study: 28751559

Group type: EXPERIMENTAL
Intervention: Loss-of-function mutations of IKZF1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dominant-negative mutations of IKZF1
Number of subjects: 0
Study: 28751763

Group type: EXPERIMENTAL
Intervention: Four or more risk factors
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Maternal pre-pregnancy overweight status
Number of subjects: 858

Group type: EXPERIMENTAL
Intervention: Paternal overweight status
Number of subjects: 858
Study: 28752370

Group type: EXPERIMENTAL
Intervention: L-NMMA and diclofenac
Number of subjects: 58

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 58
Study: 28752679

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of autologous stimulated bone marrow stem cells (BM-SC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Oral acetaminophen (Control group)
Number of subjects: 61
Study: 28752805

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs supplementation (1800 mg daily for 12 weeks, containing 1206 mg eicosapentaenoic acid and 609 mg docosahexaenoic acid)
Number of subjects: 13
Study: 28753486

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10mg/day
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg/day
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Empagliflozin (both doses)
Number of subjects: 1403
Study: 28753747

Group type: EXPERIMENTAL
Intervention: Degarelix therapy for 7 months
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Reduced two-factor model (baseline PSA, age)
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: End of induction period (EOI) PSA
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: Testosterone recovery
Number of subjects: 191
Study: 28753830

Group type: EXPERIMENTAL
Intervention: Intracavernous autologous bone marrow mononuclear cells (BM-MNCs) injected at an optimal dose of 1×10^6 cells.
Number of subjects: 18
Study: 28754178

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging combined with skin iontophoresis of acetylcholine (endothelium-dependent vasodilator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser speckle contrast imaging combined with skin iontophoresis of sodium nitroprusside (endothelium-independent vasodilator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional capillary density assessment by video-microscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-occlusive reactive hyperemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group of sex- and age-matched healthy volunteers
Number of subjects: 0
Study: 28754476

Group type: EXPERIMENTAL
Intervention: Designated women's health provider
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stronger self-efficacy beliefs about screening women for MST
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Seeing women patients at least once per week
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Stronger self-efficacy beliefs about screening women for IPV
Number of subjects: 281
Study: 28754494

Group type: EXPERIMENTAL
Intervention: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly by needle-syringe or needle-free devices, doses ranging from 80-640 μg, with three doses and a booster after 1 year.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: CV7201 (mRNA rabies vaccine) administered intradermally or intramuscularly, doses of 80 μg or 160 μg intradermally and 200 μg or 400 μg intramuscularly.
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Booster dose of 80 μg CV7201 administered needle-free intradermally after 1 year.
Number of subjects: 101

Group type: COMPARATOR
Intervention: Intradermal or intramuscular needle-syringe injection of CV7201.
Number of subjects: 101
Study: 28754534

Group type: EXPERIMENTAL
Intervention: Drug-eluting beads loaded with doxorubicin (DEBDOX)
Number of subjects: 20
Study: 28754808

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 9012

Group type: COMPARATOR
Intervention: Men
Number of subjects: 9012

Group type: EXPERIMENTAL
Intervention: Women (after adjustment)
Number of subjects: 9012
Study: 28754833

Group type: EXPERIMENTAL
Intervention: Dolichoectasia
Number of subjects: 3850
Study: 28755137

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate 100 µG once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate 250 µG twice daily
Number of subjects: 0
Study: 28755256

Group type: EXPERIMENTAL
Intervention: Local excision for patients with mCR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local excision or watch and wait policy for patients with cCR
Number of subjects: 0
Study: 28755389

Group type: EXPERIMENTAL
Intervention: Dulaglutide 2.0 mg for 6 months
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Dulaglutide therapy
Number of subjects: 1
Study: 28755782

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg once monthly)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Teriparatide (20 μg once daily)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 436

Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 436
Study: 28755959

Group type: EXPERIMENTAL
Intervention: Intravesical CG0070
Number of subjects: 45
Study: 28756065

Group type: EXPERIMENTAL
Intervention: Atrasentan 0.75 mg/d
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 28756183

Group type: EXPERIMENTAL
Intervention: Menaquinone-7 (vitamin K2) supplementation (360 μg once daily) for 8 weeks
Number of subjects: 60
Study: 28757156

Group type: EXPERIMENTAL
Intervention: Bronchial Thermoplasty (BT)
Number of subjects: 0
Study: 28757639

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 56
Study: 28758370

Group type: EXPERIMENTAL
Intervention: Remote Food Photography Method (RFPM)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Doubly Labeled Water (DLW) method
Number of subjects: 39
Study: 28759304

Group type: EXPERIMENTAL
Intervention: Third molar extraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no third molars)
Number of subjects: 40
Study: 28760151

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (14 preoperative sessions and 39 postoperative sessions)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard care (one educational session and early inpatient postoperative physiotherapy)
Number of subjects: 140
Study: 28760152

Group type: EXPERIMENTAL
Intervention: S-1 maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuation of the same regimen as during the primary period
Number of subjects: 0
Study: 28760533

Group type: EXPERIMENTAL
Intervention: Hyperemia score
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Tsuga score
Number of subjects: 58
Study: 28760541

Group type: EXPERIMENTAL
Intervention: Behavioral intervention for insomnia
Number of subjects: 0
Study: 28760669

Group type: EXPERIMENTAL
Intervention: Recombinant BFL-associated proteins (IGLL1)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Recombinant BFL-associated proteins (ProE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Precipitin assays with pigeon dropping extracts
Number of subjects: 55
Study: 28760834

Group type: EXPERIMENTAL
Intervention: Quality indicator score for advance care planning
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Quality indicator score for goals-of-care discussions
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Overall quality indicator score
Number of subjects: 506
Study: 28761384

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 463

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 463
Study: 28761581

Group type: EXPERIMENTAL
Intervention: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release, bilayer tablets for 7 consecutive days
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Placebo for 7 consecutive days
Number of subjects: 1179

Group type: EXPERIMENTAL
Intervention: 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release
Number of subjects: 1179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1179
Study: 28761651

Group type: EXPERIMENTAL
Intervention: Fasting during Ramadan
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Self-adjusted medication during fasting
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Diet management during fasting
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Collaboration with religious authorities
Number of subjects: 53
Study: 28761660

Group type: EXPERIMENTAL
Intervention: DASH dietary pattern (DASH score)
Number of subjects: 15942
Study: 28761662

Group type: EXPERIMENTAL
Intervention: Two eggs/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Egg exclusion
Number of subjects: 34
Study: 28761675

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 18624

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 18624
Study: 28761678

Group type: EXPERIMENTAL
Intervention: Polymer-free sirolimus-eluting stent (PF-SES)
Number of subjects: 2877
Study: 28761685

Group type: EXPERIMENTAL
Intervention: Dual-therapy stent
Number of subjects: 1000
Study: 28761697

Group type: EXPERIMENTAL
Intervention: Physical activity intervention program (strenuous physical exercise)
Number of subjects: 75
Study: 28761699

Group type: EXPERIMENTAL
Intervention: Flywheel exercise (n=9)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Inactive group (n=16)
Number of subjects: 25
Study: 28761750

Group type: EXPERIMENTAL
Intervention: Aflibercept in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Number of subjects: 1226

Group type: COMPARATOR
Intervention: Placebo in combination with FOLFIRI (infusional fluorouracil, leucovorin and irinotecan)
Number of subjects: 1226

Group type: EXPERIMENTAL
Intervention: Aflibercept
Number of subjects: 1226
Study: 28762099

Group type: EXPERIMENTAL
Intervention: Multidisciplinary childhood obesity treatment programme
Number of subjects: 1291

Group type: EXPERIMENTAL
Intervention: Increasing BMI SDS (n=315)
Number of subjects: 1291
Study: 28763344

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50-100 mg/day for 8 weeks
Number of subjects: 35
Study: 28764748

Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m) in combination with weekly trastuzumab (2 mg/kg) and paclitaxel (80 mg/m)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ganetespib (150 mg/m)
Number of subjects: 9